Axon Enterprise (NASDAQ:AXON) PT Raised to $525.00

Axon Enterprise (NASDAQ:AXON) had its target price increased by Needham & Company LLC from $400.00 to $525.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside of 18.59% from the company’s current price.

A number of other equities analysts have also commented on the stock. Robert W. Baird raised their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Northland Securities raised their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. JMP Securities upped their price target on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Craig Hallum increased their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group initiated coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $382.85.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $442.69 on Tuesday. The stock’s fifty day simple moving average is $393.29 and its 200 day simple moving average is $334.66. The stock has a market capitalization of $33.45 billion, a price-to-earnings ratio of 116.81, a PEG ratio of 11.74 and a beta of 0.94. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise has a 52-week low of $199.29 and a 52-week high of $455.17.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter last year, the business posted $0.80 EPS. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. As a group, sell-side analysts forecast that Axon Enterprise will post 1.79 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at $1,121,052,771.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Patrick W. Smith sold 75,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $356.53, for a total transaction of $26,739,750.00. Following the completion of the sale, the chief executive officer now owns 2,970,366 shares in the company, valued at $1,059,024,589.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 371,172 shares of company stock valued at $137,000,162. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Avantax Advisory Services Inc. boosted its holdings in Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares during the period. GSA Capital Partners LLP acquired a new stake in Axon Enterprise during the first quarter worth about $931,000. Zurich Insurance Group Ltd FI increased its stake in Axon Enterprise by 1.9% during the second quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock valued at $60,324,000 after acquiring an additional 3,832 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Axon Enterprise by 14.8% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after acquiring an additional 22,013 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after acquiring an additional 1,634 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.